{"id":"nicotine-mini-lozenge-for-11-months","safety":{"commonSideEffects":[{"rate":null,"effect":"Mouth irritation"},{"rate":null,"effect":"Hiccups"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicotine is a nicotinic acetylcholine receptor agonist that mimics the effects of nicotine from cigarettes, thereby reducing the intensity of withdrawal symptoms and cravings when a smoker quits. The mini-lozenge formulation allows for flexible, on-demand dosing to manage breakthrough cravings throughout the day. This approach helps maintain abstinence by providing nicotine replacement without the harmful combustion products of tobacco smoke.","oneSentence":"Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:11.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation aid"}]},"trialDetails":[{"nctId":"NCT04199117","phase":"PHASE4","title":"Health Systems Reach Interventions Project","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-03-11","conditions":"Smoking, Cigarette, Smoking Cessation","enrollment":210},{"nctId":"NCT02354872","phase":"PHASE4","title":"Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-01","conditions":"Smoking, Motivation, Smoking Cessation","enrollment":577},{"nctId":"NCT02564315","phase":"PHASE4","title":"The Long-Term Quitting (Smoking Cessation) Study","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-10-30","conditions":"Smoking Cessation","enrollment":1154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nicotine Mini-Lozenge"],"phase":"marketed","status":"active","brandName":"Nicotine Mini-Lozenge for 11 Months","genericName":"Nicotine Mini-Lozenge for 11 Months","companyName":"University of Wisconsin, Madison","companyId":"university-of-wisconsin-madison","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid for up to 11 months of treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}